A Nomogram Based on Apelin-12 for the Prediction of Major Adverse Cardiovascular Events after Percutaneous Coronary Intervention among Patients with ST-Segment Elevation Myocardial Infarction

Table 1

Participant characteristics in evaluation and validation cohorts.

Variables	Evaluation cohort (n = 324)	Validation cohort (n = 136)	-value
Age (years)	62.60 ± 12.00	63.73 ± 11.70	0.3537
Male, n (%)	250 (77.16%)	103 (75.74%)	0.7425
Killip’s classification > I, n (%)	92 (28.40%)	20 (14.71%)	0.0018
Diabetes mellitus, n (%)	99 (30.56%)	49 (36.03%)	0.2523
Hypertension, n (%)	195 (60.19%)	69 (50.74%)	0.0617
Myocardial infarction history, n (%)	37 (11.42%)	18 (13.24%)	0.5834
Anterior wall myocardial infarction, n (%)	160 (49.38%)	69 (50.74%)	0.7903
Apelin-12 (ng/mL)	0.82 ± 0.33	0.84 ± 0.35	0.5605
Apelin-12 change rate (%)	13.74 ± 8.98	12.94 ± 8.63	0.3783
SBP(mmHg)	131.34 ± 27.20	133.13 ± 27.10	0.5194
Albumin (g/L)	37.95 ± 3.92	37.87 ± 3.64	0.8385
Haemoglobin (g/L)	143.46 ± 17.39	144.65 ± 16.79	0.499
Total cholesterol (mmol/L)	5.67 ± 1.11	5.65 ± 1.06	0.8583
Triglyceride (mmol/L)	1.09 ± 0.85	1.16 ± 0.82	0.4159
High-density lipoprotein-C (mmol/L)	1.19 ± 0.27	1.24 ± 0.26	0.0676
Low-density lipoprotein-C (mmol/L)	3.06 ± 0.71	3.00 ± 0.76	0.4184
Fasting blood glucose (mmol/L)	7.63 ± 2.52	7.76 ± 2.57	0.6159
White blood cells × 10^9/L	9.95 ± 3.72	10.40 ± 3.44	0.2269
Heart rate	77.54 ± 16.97	75.42 ± 17.56	0.2268
Neutrophil (%)	75.2 ± 11.71	76.89 ± 11.03	0.1515
Creatinine (mmol/L)	75.40 ± 25.20	72.91 ± 15.58	0.2855
Uric acid (mmol/L)	339.19 ± 75.20	332.5 ± 70.63	0.376
Platelet × 10^9/L	232.59 ± 56.05	231.14 ± 57.02	0.8012
Blood urea nitrogen (mmol/L)	6.66 ± 2.05	6.89 ± 2.12	0.2776
Peak creatine kinase MB (U/L)	126.83 ± 91.26	130.85 ± 85.75	0.661
Peak cTnI (ng/ML)	16.66 ± 12.87	16.47 ± 12.86	0.8852
Pathological Q wave, n (%)	154 (47.53%)	67 (49.26%)	0.735
GENSINI score	72.92 ± 32.17	70.18 ± 32.18	0.405
Left atrial diameter (mm)	37.53 ± 5.59	37.17 ± 5.90	0.5356
Left ventricular diastolic diameter (mm)	50.36 ± 6.24	50.51 ± 6.36	0.8151